Aquestive Therapeutics, Inc.
AQST · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $13 | $10 | $9 | $12 |
| % Growth | 28% | 14.7% | -26.5% | – |
| Cost of Goods Sold | $5 | $5 | $4 | $5 |
| Gross Profit | $8 | $5 | $5 | $7 |
| % Margin | 64.8% | 54.4% | 58.1% | 61.9% |
| R&D Expenses | $5 | $4 | $5 | $5 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $15 | $13 | $19 | $16 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $20 | $17 | $24 | $21 |
| Operating Income | -$11 | -$11 | -$19 | -$14 |
| % Margin | -89.6% | -113.6% | -222.1% | -114.4% |
| Other Income/Exp. Net | -$4 | -$2 | -$4 | -$3 |
| Pre-Tax Income | -$15 | -$14 | -$23 | -$17 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$15 | -$14 | -$23 | -$17 |
| % Margin | -120.6% | -135.4% | -263% | -143.7% |
| EPS | -0.14 | -0.14 | -0.24 | -0.19 |
| % Growth | 0% | 41.7% | -26.3% | – |
| EPS Diluted | -0.14 | -0.14 | -0.24 | -0.19 |
| Weighted Avg Shares Out | 111 | 99 | 95 | 91 |
| Weighted Avg Shares Out Dil | 111 | 99 | 95 | 91 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $1 | $1 |
| Interest Expense | $4 | $4 | $4 | $4 |
| Depreciation & Amortization | $0 | $0 | $3 | $0 |
| EBITDA | -$11 | -$9 | -$16 | -$13 |
| % Margin | -86.2% | -91.3% | -180.8% | -107% |